Iovance Biotherapeutics
IOVA
81 hedge funds and large institutions have $361M invested in Iovance Biotherapeutics in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 31 increasing their positions, 25 reducing their positions, and 6 closing their positions.
759% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $139K
216% more capital inflows, than outflows
Capital inflows: $53.2M | Capital outflows: $16.8M
24% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.98% less ownership
Funds ownership: 79.86% → 77.89% (-2%)
7% less funds holding
Funds holding: 87 → 81 (-6)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$44.5M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$1.65M |
| 3 |
Goldman Sachs
New York
|
+$1.45M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$1.45M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.62M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.89M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.22M |
| 4 |
First Eagle Investment Management
New York
|
-$1.04M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.01M |
IOVA Hedge Fund Activity: Q1 2017 in Review
81 of the 4,035 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2017, worth a combined $361M — up 4.7% from $345M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of IOVA and 5 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 31 added.
The largest buyer was BlackRock, adding an estimated $44.5M. The largest seller was Fidelity Investments, cutting an estimated $4.62M.
- 81 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2017, down from 87 in Q4 2016.
- Funds reported $361M of Iovance Biotherapeutics stock for Q1 2017, up 4.7% quarter-over-quarter.
- 5 funds opened new Iovance Biotherapeutics positions in Q1 2017 and 6 closed out, a net change of -1 holder.
- The largest Iovance Biotherapeutics buyer in Q1 2017 was BlackRock, an estimated $44.5M added.
- The largest Iovance Biotherapeutics seller in Q1 2017 was Fidelity Investments, an estimated $4.62M sold.
Based on aggregated 13F filings for Q1 2017.